Topics

Servier gains non-Hodgkin lymphoma drug from CTI BioPharma

11:45 EDT 3 Oct 2019 | Pharmafile

French pharma-giant Servier has purchased the medication Pixuvri, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma.

Pixuvri is a cytotoxic drug designed to inhibit the DNA within cells thereby preventing them from making more DNA copies, which in turn blocks cancer cells from dividing and leads to their death.

The drug currently possesses European regulatory approval as monotherapy to treat adults with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.

read more

Original Article: Servier gains non-Hodgkin lymphoma drug from CTI BioPharma

NEXT ARTICLE

More From BioPortfolio on "Servier gains non-Hodgkin lymphoma drug from CTI BioPharma"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...